Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled study of PXT3003 in Charcot-Marie-Tooth disease type 1A
NL-OMON46863Phase 3Active, not recruiting
- Sponsor
- Pharnext
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baclofen, naltrexone and sorbitol in Charcot-Marie-Tooth disease type 1A (CMT1A), sponsored by Pharnext. Primary endpoint: Change in disability measured by Overall Neuropathy Limitation Scale. Started Aug 2016; status: active, not recruiting.
02
Drugs
baclofennaltrexonesorbitol
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NL-OMON46863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46863.